Northwire Canada EditionTuesday, August 25, 2026
Northwire
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Neutral

The Medicus Pension Plan reports 140% funded status and 13.7% investment return

Scotiabank’s earnings engine revs higher, but a physician‑plan headline leaves investors unimpressed.

Executive Summary
  • The latest item (June 3, 2026) reports that the Medicus Pension Plan achieved a 140% funded status, a 13.7% investment return in 2025, and 100% inflation protection for the fourth straight year.
  • The release mentions a physician‑focused registered pension plan with governing board composition, legislative efforts for expansion, and enhanced member benefits.
  • No reference to Scotiabank’s operations, financials, or strategy appears anywhere in the announcement. The connection to BNS is presumed to stem from a wealth‑management or administration role, but the release itself is entirely about Medicus.
Material Impact
  • There is no quantifiable impact on Scotiabank’s revenue, net income, capital ratios, or earnings per share.
  • The news does not alter the bank’s credit profile, liquidity position, growth outlook, or capital return trajectory.
  • In the context of the very strong Q2‑2026 results (net income +30% YoY, adjusted EPS of $2.02) and a series of accretive operating updates, this item is effectively background noise.
  • The market’s attention will remain on earnings momentum, credit‑cost normalization, and the MapleMark acquisition; this headline will not move the stock.
BNS · Price
Company Overview
  • Scotiabank is one of Canada’s Big Five banks, operating through Canadian Banking, International Banking (Pacific Alliance focus), Global Wealth Management, and Global Banking & Markets.
  • The strategy is centered on organic earnings growth, improving Canadian Banking ROE toward ~24% by 2028, scaling the U.S. presence (KeyCorp investment and MapleMark acquisition), and exiting non‑core Latin American markets (the Colombia/Costa Rica/Panama divestiture closed in late 2025).
  • The medium‑term target of 14%+ ROE is now expected by fiscal 2027, a year ahead of plan, per management’s Q1‑2026 call.
Read the original news release →

More from BANK OF NOVA SCOTIA (THE)